Aimmune Therapeutics

We are a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization ImmunoTherapy, or CODITTM, is designed to desensitize patients to food allergens and thereby reduce the risk of having an allergic reaction upon accidental exposure, or reduce symptom severity should an allergic reaction occur. CODIT is intended to reduce meaningfully the burden and anxiety experienced by food-allergic patients and their families.

Market capitalization(2018-06-14)

$1.7 B

Type

Public

Brisbane, US

Founded

2011

Size (employees)

122 (est)+20%

Website

aimmune.com

Aimmune Therapeutics was founded in 2011 and is headquartered in Brisbane, US

Report incorrect company information

Key People/Management at Aimmune Therapeutics

Daniel C. Adelman

Chief Medical Officer

Sue Barrowcliffe

General Manager of Europe

Eric Bjerkholt

CFO

Jayson Dallas

President and Chief Executive Officer

Becki Filice

SVP, Product and Portfolio Management

Mary Rozenman

SVP, Corporate Development and Strategy

Report incorrect company information

Aimmune Therapeutics Office Locations

Aimmune Therapeutics has offices in Greater London and Brisbane

Brisbane, US (HQ)

200 8000 Marina Blvd

Greater London, GB

344-354 Grays Inn Rd

Show all (2)

Report incorrect company information

Aimmune Therapeutics Financials and Metrics

Aimmune Therapeutics Financials

Summary

USD
Net income (Q1, 2018)	(49.5 m)
EBIT (Q1, 2018)	(50.1 m)
Market capitalization (14-Jun-2018)	1.7 b
Closing share price (14-Jun-2018)	29.8
Cash (31-Mar-2018)	209.3 m

Aimmune Therapeutics's current market capitalization is $1.7 b.

Income Statement

Annual

USD	FY, 2015	FY, 2016
General and administrative expense	16.2 m	26.9 b
R&D expense	19.8 m	54.6 b
Operating expense total	36 m	81.5 b
EBIT	(36 m)	(81.5 b)

Quarterly

USD	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q1, 2018
General and administrative expense	5.2 m	5.7 m	6.5 m	6.4 m	8.9 m	10.8 m	16.7 m
R&D expense	3.9 m	10 m	11.8 m	15.9 m	17.4 m	22.2 m	33.4 m
Operating expense total	9 m	15.7 m	18.3 m	22.2 m	26.3 m	33 m	50.1 m
EBIT	(9 m)	(15.7 m)	(18.3 m)	(22.2 m)	(26.3 m)	(33 m)	(50.1 m)

show all

Balance Sheet

Annual

USD	FY, 2015	FY, 2016
Cash	76.7 m	124 m
Inventories	5.6 m	2.7 m
Current Assets	197.5 m	251.7 m
PP&E	2.7 m	10.4 m

Quarterly

USD	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q1, 2018
Cash	58.5 m	112.7 m	65 m	74.4 m	76.9 m	78.7 m	84.5 m	209.3 m
Current Assets	60.6 m	217.8 m	185.2 m	172.8 m	152.6 m	248.9 m	242.6 m	330.3 m
PP&E	1.3 m	1.8 m	3.7 m	7 m	9 m	11.1 m	13.1 m	21 m
Total Assets	62.1 m	222.8 m	199.9 m	185.7 m	173.7 m	276.3 m	256.4 m	361.8 m

show all

Cash Flow

Annual

USD	FY, 2015	FY, 2016
Net Income	(35.8 m)	(80.8 m)
Depreciation and Amortization	115 k	534 k
Inventories		4 m
Accounts Payable	1.1 m	(994 k)

Quarterly

USD	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q1, 2018
Net Income		(9 m)	(15.5 m)	(18.1 m)	(22.1 m)	(25.9 m)	(49.5 m)
Depreciation and Amortization							356 k
Accounts Payable	309 k	1 m	1.8 m	1.3 m	1.5 m	1.7 m	(431 k)
Cash From Operating Activities							(39.8 m)